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Rune Smaaland1 and Oddmund Nordgård1,5*Abstract
Background: To investigate the prognostic significance of disseminated tumor cells (DTCs) in bone marrow (BM)
from non-metastatic breast cancer patients before and after surgery.
Methods: Patients with non-metastatic breast cancer were consecutively recruited to this project during the years
1998–2000. Real-time RT-PCR quantification of a DTC multimarker panel consisting of cytokeratin 19, mammaglobin
A and TWIST1 mRNA was performed in BM samples obtained from 154 patients three weeks (BM2) and/or six
months after surgery (BM3). The results were compared to previously published data from pre-operative BM
analyses for the same patients.
Results: DTCs were identified in post-operative BM samples (BM2 and/or BM3) from 23 (15%) of the 154 patients
investigated. During a median follow-up of 98 months, 10 (44%) of these patients experienced systemic relapse as
compared to 16 (12%) of 131 DTC-negative patients. Kaplan-Meier estimates of systemic recurrence-free- and
breast-cancer specific survival demonstrated significantly shorter survival for patients with persistent DTCs in BM
after surgery (p≤0.001). By multivariate Cox regression analyses, persistent DTCs after surgery was an independent
predictor of both systemic recurrence-free- (HR = 5.4, p< 0.001) and breast-cancer specific survival (HR = 5.3,
p< 0.001). Furthermore, the prognostic value of DTCs in BM was similar for pre- and post surgery samples.
However, patients with DTCs both before and after surgery (BM1 and BM2/3) had a particularly poor prognosis
(systemic recurrence-free survival: HR = 7.2, p< 0.0001 and breast-cancer specific survival: HR = 8.0, p< 0.0001).
Conclusions: Detection of persistent DTCs in BM samples obtained after surgery identified non-metastatic breast
cancer patients at high risk for systemic relapse, and with reduced breast-cancer specific survival. Furthermore,
patients with positive DTC status both before and after surgery had a particularly poor prognosis.
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There is considerable evidence that detection of dissemi-
nated tumor cells (DTCs) in pre-operative bone marrow
(BM) samples from non-metastatic breast cancer
patients identifies a patient population at high risk for
disease recurrence [1-5]. DTCs have also been found in
the BM after surgery, both before and after adjuvant* Correspondence: nood@sus.no
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reproduction in any medium, provided the ortreatment [6-12]. The shedding of cells observed from
primary tumors should be expected to end after removal
of the tumor by surgery. Thus, DTCs detected after rad-
ical surgery in patients without evidence of distant me-
tastases must originate from occult metastases or be
able to persist in the BM after surgery. DTCs which per-
sist post-operatively after surgery, and even after com-
pletion of adjuvant treatment, may be enriched for
tumor cells with better capability to survive, and also
grow, in the secondary site. Accordingly, it has been
demonstrated that a large fraction of the breast cancer
DTCs has a stem cell-like phenotype [13,14], which mayal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[15]. Thus, both a prognostic and a predictive value of
BM DTC detection after surgery seem likely. Further-
more, one may hypothesize that repeated BM sampling
in order to detect DTCs, in particular following adminis-
tration of adjuvant treatment, may improve the predic-
tion of disease recurrence and the selection of patients
who might benefit from secondary or intensified adju-
vant treatment.
There is limited evidence of the clinical usefulness of
the suggested repeated BM sampling. Two studies, both
using immunocytochemical detection methods, have
reported the results of repeated BM sampling performed
in women who were recurrence-free 2–3 years after pri-
mary diagnosis. The presence of DTCs in this group of
patients significantly predicted shorter distant disease-
free survival, but the prognostic impact seemed similar
to that obtained from pre-operative analyses [6,7]. To se-
lect patients who would benefit by secondary adjuvant
treatment, repeated BM sampling at an earlier time
might be preferable. One such study has been reported
by Daskalaki et al. (2009), with samples collected before
and after adjuvant chemotherapy [10]. In contrast to the
two prior studies, this group used real-time RT-PCR
quantification of cytokeratin 19 (CK19) transcripts to
detect DTCs. They observed a survival difference
according to DTC status both before and after chemo-
therapy, however, the difference between the DTC posi-
tive and negative groups was statistically significant only
for the BM samples obtained before chemotherapy [10].
In the present study, we have used real-time RT-PCR
quantification of a multimarker (MM) mRNA panel to
detect DTCs in BM. The use of our MM mRNA panel is
expected to result in high sensitivity since the markers
may be differentially expressed in breast cancer cells.
Previously we have demonstrated, using our MM mRNA
panel, that detection of DTCs in pre-operative BM sam-
ples predicts clinical outcome in non-metastatic breast
cancer patients [16]. The present study is the first
reporting repeated post-operative BM samples from
non-metastatic breast cancer patients assessed by a MM
quantitative RT-PCR assay for DTC detection. The BM
samples were obtained three weeks and six months after
surgery from 154 patients. Having 98 months (>8 years)
median follow-up data for the patients, we have evalu-
ated the prognostic significance of persistent DTCs in
BM after surgery, and compared the prognostic and pre-
dictive information associated with the different sam-
pling time points.Methods
This study is reported according to the recommenda-
tions for tumor marker prognostic studies [17].Patient cohort
Initially 234 patients (median age 56 years, range 25–86
years) with non-metastatic breast cancer (M0) were con-
secutively recruited to this project during the period
1998–2000. However, forty-three patients were excluded
from the study; 25 patients with either ductal carcinoma
in situ (DCIS) or lobular carcinoma in situ (LCIS), 7
patients with benign lesions, one patient with primary
metastatic disease and 10 patients with missing BM
samples. The prognostic impact of DTCs in BM samples
obtained prior to surgery (BM1) has previously been
evaluated in the remaining 191 patients [16,18,19].
In the present study, we have analyzed additional BM
samples (20 mL in heparin anticoagulant) that were
obtained by unilateral aspiration from the posterior iliac
crest under local anesthesia three weeks (denoted BM2),
and six months (denoted BM3) after primary surgery.
However, after surgery only 144 of the 191 included
patients consented to having a second BM aspiration
(BM2), while 109 patients agreed to undergo a third BM
aspiration (BM3). In total, BM2 and/or BM3 aspirates
were obtained from 154 patients (for more details see
Table 1), and 99 patients allowed aspirations at all three
time points.
The patients were treated according to the Norwegian
National guidelines at that time, and the treatment and
clinical follow-up of the patients were done systematic-
ally as previously described [18]. In detail, 30 of the 99
patients received adjuvant chemotherapy and 34 patients
received adjuvant endocrine therapy. Due to some over-
lap between the treatment groups, 44 of 99 patients
received adjuvant endocrine- and/or adjuvant chemo-
therapy, whereas 55 did not receive any adjuvant
treatment.
Follow-up data for all patients were collected from the
hospital records and from their primary physician’s
records. The control program for the patients was
according to the routines of the institution, with one to
two visits per year, depending on patient age, stage,
breast conserving treatment versus mastectomy, time
from primary treatment and method of diagnosis
(screening-detected vs. not). Blood tests were performed
1–2 times per year, in addition to mammography exam-
ination once a year. Information on time of death was
obtained from the Hospital records, through an auto-
matic update from the National Registry in Norway. The
cause of death was determined from the medical files at
the hospital, or by information from the patients’ pri-
mary physicians [19]. The end of the follow-up period
was October 2008, and the median follow-up time was
98 months (range 1–127 months). The project was
approved by the Regional Committees for Medical and
Health Research Ethics, and written informed consent
was obtained from all participating patients. Single BM











<=55 years 78 6 (8) 72 (92)
>55 years 76 17 (22) 59 (78)
Lymph node status 0.223
pN0 110 14 (13) 96 (87)
pN1-2 44 9 (20) 35 (80)
Tumor size 0.469
pT1 105 14 (13) 91 (87)
pT2-4 49 9 (18) 40 (82)
Tumor grade 0.803
1 55 8 (14) 47 (86)
2 61 10 (16) 51 (84)
3 35 4 (11) 31 (89)
Unknown 3
Estrogen receptor status 0.365
ER positive 127 17 (13) 110 (87)
ER negative 25 5 (20) 20 (80)
Unknown 2
Progesterone receptor status 0.105
PgR positive 76 15 (20) 61 (80)
PgR negative 75 7 (9) 68 (91)
Unknown 3
Histological type 0.182
Ductal 121 15 (12) 106 (88)
Lobular 15 3 (20) 12 (80)
Mixed ductal/lobular 5 1 (20) 4 (80)
Other 13 4 (31) 9 (69)
Chemotherapy 0.798
Therapy 41 5 (12) 36 (88)
No therapy 113 18 (16) 95 (84)
Endocrine therapy 0.336
Therapy 47 9 (18) 38 (81)
No therapy 107 14 (13) 93 (87)
Numbers in brackets represent the number of patients in percent.
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the control group.
RNA isolation and cDNA synthesis
BM lysates were prepared from buffy coat as previously
described [20]. Total RNA was isolated, and A260/A280
ratios measured (range 1.9–2.0). For a subset of the sam-
ples the RNA quality was also measured on the Agilent2100 Bioanalyzer (range RIN= 8.2–9.3). Afterwards, the
RNA was treated with DNase I and reverse transcribed
to cDNA [18]. All cDNA samples were stored at −80°C.
qRT-PCR
Amplification of the MM panel consisting of CK19
(NM_002276), hMAM (U33147) and TWIST1
(NM_000474) mRNA was performed as described
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sensitivity for hMAM mRNA detection, we increased
the cDNA content from 20 to 50 ng, and reduced the
primer concentration to 0.3 μM compared to that previ-
ously described by Tjensvoll et al. (2009) [19]. Quantifi-
cation of the three mRNA markers was performed,
blinded for the identity and clinical outcome of the
patients, in a LightCycler 480 (Roche Applied Science)
instrument. The breakpoint cluster region (BCR,
NM_004327) was used as a reference gene. CK19 and
TWIST1 were analysed in duplicates, while hMAM was
analysed in triplicates.
Relative mRNA quantification
mRNA concentrations, based on mean crossing point
(CP) values, were normalized against BCR mRNA level
and expressed relative to a calibrator sample as previ-
ously described [16,19]. A cut-off value was determined
for each marker based on the highest mRNA level in
BM samples of the normal control group (n = 26). The
relative hMAM and TWIST1 mRNA concentrations
have been determined previously in the BM samples
from this control group of healthy women [16,19],
whereas the CK19 mRNA concentration was measured
in the present study. The highest relative CK19 mRNA
level determined in the normal control BMs was
7.40×10−4, and this was used as a threshold for normal
mRNA level in the further analyses. BM samples were
considered as positive for DTCs when positive for at
least one of the mRNA markers (i.e. CK19, hMAM or
TWIST1).
Statistical analyses
The statistical analyses were performed in SPSS version
17.0 (www.spss.com) with a two-sided p-value ≤0.05 con-
sidered as statistically significant. P-values were not cor-
rected for multiple testing, and missing data were excluded
from the analyses. Relations between the multimarker BM
expression and various clinicopathological parameters
were tested by Fisher’s exact test. Kaplan-Meier
estimates of clinical outcome were determined forTable 2 The number of positive bone marrow (BM) samples s
mammaglobin A (hMAM), cytokeratin 19 (CK19) and TWIST1,
multimarker panel




BM1 154 0 4
BM2 144 10 6
BM3 109 45 6
BM2 and/or BM3 154 0 1
BM1 drawn prior to surgery; BM2 drawn three weeks after primary surgery; BM3 dra
The number of systemic relapse is shown in parentheses.
*Positive for at least one of the markers hMAM, CK19 and TWIST1.the time intervals from primary surgery to A) sys-
temic (distant) recurrence of the disease (systemic
recurrence-free survival) and B) death related to pro-
gression of breast cancer (breast-cancer-specific
survival).
Cox univariate and multivariate survival regression
was used to evaluate the effects of BM DTC status,
lymph node (LN) status, tumor size, tumor grade, age,
estrogen receptor (ER) status, progesterone receptor
(PR) status, adjuvant chemotherapy and endocrine ther-
apy on systemic-recurrence-free survival and breast-
cancer specific survival (see [16,19]). The multivariate
analyses were performed using both forward and back-
ward stepwise selection of covariates. The effect of each
variable in these models was assessed by the Wald test
and described by the hazard ratio (HR), with a 95% con-
fidence interval.
Results
Detection of persistent DTCs in BM samples obtained
after primary surgery
We have previously demonstrated by a MM quantitative
RT-PCR panel that detection of DTCs in pre-operative
BM samples (BM1) predicts clinical outcome in non-
metastatic breast cancer patients [16]. In order to evaluate
the presence of persistent DTCs as a marker for poor out-
come, BM samples were obtained three weeks (BM2,
n= 144) and/or six months (BM3, n= 109) after primary
surgery from 154 of the breast cancer patients (Table 1)
previously analysed for pre-operative (BM1) DTC status.
The BM sample was considered to contain DTCs (positive
DTC status) if at least one of the surrogate mRNA mar-
kers CK19, hMAM and TWIST1 had levels above the
established threshold values [16,19]. Of the 154 analysed
patients with early breast cancer, 23 (15%) patients were
DTC-positive in at least one of the post-operative BM
samples (Table 2). Potential associations between clinico-
pathological parameters and DTC status in BM after sur-
gery (at three weeks and/or six months) are shown in
Table 1. Furthermore, eight patients were DTC positive
both pre- (BM1) and post-operatively (BM2 and/or BM3),hown separately for the three mRNA markers
as well as in combination by construction of a
Marker expression Multimarker
positive*MAM CK19 TWIST1
(3) 14 (8) 5 (2) 21 (11)
(5) 5 (2) 9 (4) 17 (8)
(3) 1 (1) 2 (1) 7 (3)
1 (7) 5 (2) 11 (5) 23 (10)
wn six months after primary surgery.
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three time points was DTC positive in all three samples.
Since not all of the patients who provided a BM aspir-
ation prior to surgery agreed to provide BM aspirations
three weeks (BM2) and/or six months after surgery
(BM3), we tested by Fisher’s exact test if there were any
biases between the different sample groups included in
this study. No significant differences were found be-
tween the 45 patients only providing BM2, and the 99
patients who provided both BM2 and BM3 aspirations.
However, there was a trend (p= 0.12) towards a higher
frequency of N0 patients with lower differentiation grade
in the BM2 sampling group.
In the BM samples obtained after primary surgery the
three mRNA markers were complementary, as only four
of 154 patients had elevated levels of more than one
marker (Table 2). Furthermore, the relative contribution
of the CK19 marker to the total number of DTC positive
samples declined in the post-operative BM samples, as
compared with the contribution of this marker detected
prior to surgery (Table 2).Prognostic significance of persistent DTCs in BM after
primary surgery
During a median follow-up of 98 months, 10 out of the 23
(44%) patients with persistent DTCs detected in at least one
of the two post-operative BM samples experienced systemic
relapse (Table 2), compared with 16 of 131 (12%) patients
with negative DTC status in post-operative BM. Eight of the
10 (80%) patients with recurrent disease have subsequently
died from breast cancer. Kaplan-Meier estimates of systemic
recurrence-free survival and breast-cancer specific survival
both showed that the DTC status in BM samples obtained
after primary surgery was a strong prognostic factor (Figure 1).
A significantly shorter overall- (p=0.006) and recurrence-free
survival (p< 0.001) was also demonstrated (data not shown).
Moreover, when we stratified the Kaplan-Meier analyses of
systemic recurrence-free survival according to LN status, the
post-operative DTC status was demonstrated to be a strong
prognostic factor in both the LN-negative (p=0.007) and the
LN-positive patients (p=0.010, curves not presented).
Uni- and multivariate Cox regressions were performed
to evaluate the prognostic impact of persistent DTCs in
BM of non-metastatic breast cancer patients. In the uni-
variate analyses DTC status at all the three sampling time
points, LN status, tumor grade and ER status were signifi-
cant predictors of both systemic recurrence-free survival
and breast-cancer specific survival (Table 3). The multi-
variate analyses showed that the presence of DTCs in
post-operative BM samples, as detected by our MM
quantitative RT-PCR assay, was a strong independent
prognostic factor (Table 4) together with lymph node sta-
tus and tumor grade (data not presented). This wasdemonstrated by both forward and backward stepwise se-
lection of variables.
Comparison of the prognostic significance of DTCs in BM
samples obtained at different time points
We compared the prognostic significance of DTC detec-
tion in BM samples obtained before (BM1), three weeks
(BM2) and six months (BM3) after primary surgery by
three separate multivariate Cox regressions, also includ-
ing other prognostic factors, and found only small differ-
ences in the hazard ratios between the three time points
(Table 4). However, the number of DTC-positive patients
was substantially higher for the BM obtained before
(BM1) as well as three weeks (BM2) after surgery
(Table 4). Moreover, as suggested by the univariate Cox
regression analysis, the combination of both pre- and
post-operative positive DTC status remained a particu-
larly strong prognostic factor in the multivariate analysis
(Table 4). Kaplan-Meier survival analyses demonstrated
that patients with positive DTC status both before and
after primary surgery had an estimated 8-year systemic
recurrence-free survival and breast-cancer specific sur-
vival below 20% (Figure 2).
Discussion
We have previously demonstrated that the presence of
DTCs, in terms of MM mRNA levels above the estab-
lished cut-off values, in BM samples obtained prior to
breast cancer surgery provide significant prognostic in-
formation (HR= 3.59, p= 0.001 for systemic-recurrence-
free survival) [16]. In the present study, we have shown
that DTCs in BM samples obtained three weeks and/or
six months after surgery provide similar prognostic in-
formation as the DTC status in pre-operative BM, with
hazard ratios in the range 5.8–6.8 (Table 4). These
results were somewhat unexpected since the presump-
tive passive shedding of cells from primary tumors gives
reason to believe that a higher proportion of clinically
insignificant DTCs would be present in the BM before
surgery. In this respect, BM sampling after surgery was
expected to give more significant prognostic informa-
tion. The results of the present study confirm the prog-
nostic significance of DTCs after surgery as detected by
our real-time RT-PCR assay. Most likely, the clinical im-
portance of persistent DTCs in BM is even stronger than
observed, as some of the included patients only agreed
to one of the post-operative BM aspirations. Our results
do not, however, suggest that patients with DTCs
detected post-operatively have a prognosis that is infer-
ior to patients with DTCs detected pre-operatively.
Thus, a selection of DTCs with a higher capability of
establishing clinical overt metastases after removal of
the primary tumor, or even after six months of adjuvant
treatment, is not supported. This finding is consistent
Figure 1 Kaplan Meier estimates according to the presence of persistent disseminated tumor cells in bone marrow after surgery.
Kaplan-Meier estimates of systemic recurrence-free survival (A), and breast-cancer specific survival (B) according to positive (n = 23) and negative
(n = 131) persistent disseminated tumor cell (DTC) status in bone marrow as detected three weeks and/or six months after surgery. P-values were
calculated by the log-rank test. The numbers of patients at risk are indicated below each plot.
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estimated prognostic effect of DTCs in BM samples
collected shortly after adjuvant chemotherapy was simi-
lar to the effect in BM samples collected post-
operatively, prior to chemotherapy [10]. Similarly, the
impact of DTCs in BM samples obtained 2–3 years after
diagnosis seemed to have a similar magnitude as that
observed pre-operatively [2,5-7].The results in the present study do, however, suggest
that a positive pre-operative DTC status, if confirmed in
a second BM sample collected three weeks or six
months post-operatively (double positive), predicts a
particularly poor prognosis. The estimated 8-year sys-
temic recurrence-free survival in this group of patients
was in fact <20% (Figure 2A), as compared to >50% in
the group defined as DTC positive based on post-
able 3 Univariate Cox regression analyses of systemic-recurrence-free survival and breast-cancer specific survival
M samples Parameter Hazard ratio 95% CI P-values
Systemic recurrence-free survival
M1 DTC status (pos. vs. neg.) 5.944 2.713–13.022 <0.001
M2* DTC status (pos. vs. neg.) 5.013 2.133–11.782 <0.001
M3* DTC status (pos. vs. neg.) 3.680 1.062–12.744 0.040
M2 and/or BM3 DTC status (pos. vs. neg.) 4.523 2.044–10.008 <0.001
M1 and BM2/3 DTC status (pos. vs. neg.) 9.948 4.103–24.122 <0.001
Lymph node status (pN> 0 vs. pN0) 3.995 1.833–8.708 <0.001
Tumor size (pT3 and pT4 vs. pT2 vs. pT1) 1.523 0.691–3.358 0.297
Tumor grade (3 vs. 2 vs. 1) 2.015 1.212–3.352 0.007
Age (>55 or not) 1.044 0.484–2.252 0.913
ER (positive vs. negative) 0.322 0.143–0.723 0.006
PgR (positive vs. negative) 0.735 0.337–1.605 0.440
Adjuvant chemotherapy (received or not) 1.603 0.713–3.601 0.253
Adjuvant endocrine therapy (received or not) 1.814 0.832–3.951 0.134
Breast-cancer specific survival
M1 DTC status (pos. vs. neg.) 5.408 2.271–12.880 <0.001
M2* DTC status (pos. vs. neg.) 3.880 1.470–10.238 0.006
M3* DTC status (pos. vs. neg.) 4.626 1.286–16.635 0.019
M2 and/or BM3 DTC status (pos. vs. neg.) 3.851 1.592–9.316 0.003
M1 and BM2/3 DTC status (pos. vs. neg.) 9.205 3.526–24.031 <0.001
Lymph node status (pN> 0 vs. pN0) 4.694 1.944–11.344 0.001
Tumor size (pT3 and pT4 vs. pT2 vs. pT1) 1.788 0.753–4.247 0.188
Tumor grade (3 vs. 2 vs. 1) 3.288 1.743–6.201 <0.001
Age (>55 or not) 1.384 0.583–3.284 0.461
ER (positive vs. negative) 0.217 0.091–0.516 0.001
PgR (positive vs. negative) 0.729 0.306–1.733 0.474
Adjuvant chemotherapy (received or not) 1.545 0.623–3.833 0.348
Adjuvant endocrine therapy (received or not) 1.820 0.766–4.324 0.175
M1 drawn prior to surgery, BM2 drawn three weeks after surgery, BM3 drawn six months after surgery;BM bone marrow; DTC disseminated tumor cell; ER
strogen receptor; PgR Progesterone receptor; BM2/3 BM2 and/or BM3.
only patients with this sample available were included in the analysis.















*operative BM samples alone (Figure 1A). A similar trend
was reported by Wiedswang et al. (2004), although it was
not as striking as in our study. In their study, the estimated
5-year distant disease-free survival was <70% for the
patients with DTC-positive BM both at diagnosis and after
three years, as compared to ~80% for the whole group of
patients who were DTC positive only in the second BM
sample [6]. However, the fact that they obtained the
follow-up BM samples three years after surgery, and thus
excluded the patients with recurrence during this 3-year
interval, must be considered when comparing their esti-
mated survival rates with ours. Our group of patients, with
DTC positive BM both before and after surgery, includedboth LN-positive and LN-negative (N0) patients, the tumor
size varying from T1-T4 with grade 1–3. Hence, these
patients constituted a very heterogeneous group not neces-
sarily destined to experience an unfavorable clinical out-
come based on conventional prognostic factors.
It would be interesting to investigate whether DTC de-
tection after adjuvant therapy could be a surrogate mar-
ker for evaluation of treatment efficiency. However, due
to small patient numbers in the subgroups receiving ad-
juvant treatment it was not possible to conclude on the
potential for monitoring or prediction of adjuvant treat-
ment efficiency in this study. This important aspect
should be addressed in new studies.
Table 4 Multivariate Cox regression analyses of systemic recurrence-free survival, and breast-cancer specific survival




Systemic recurrence-free survival Breast-cancer specific survival
Hazard ratio P-values Hazard ratio P-values
BM1 16% 6.420 <0.001 7.081 <0.001
BM2 12% 5.793 <0.001 6.455 0.001
BM3 6% 6.841 0.004 4.888 0.022
BM2 and/or BM3 15% 5.397 <0.001 5.303 <0.001
BM1 and BM2/3 5% 7.188 <0.001 8.018 <0.001
BM1 drawn prior to surgery; BM2 drawn three weeks after surgery; BM3 drawn six months after surgery.
The different BM samples were included in the models in separate regression experiments. Only results from backward stepwise selection of variables are
presented.
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DTCs could make it difficult to compare studies using
different methodologies. Immunocytochemistry has the
advantages of being able to characterize cell size, cell
shape and atypical enlargement of nucleus which may
occur in malignant cells. However, due to the absence of
tumor-specific targets, monoclonal antibodies against
various epithelium-specific antigens, like the cytokera-
tins, are mostly used. In comparison, molecular methods
are highly sensitive and may detect DTCs based on their
expression of tumor-specific markers. One disadvantage
is nevertheless that the cells cannot be morphologically
characterized by the use of molecular methods. How-
ever, molecular profiling of breast cancer cells may be
used to characterize and classify the tumor cells accord-
ing to their protein, DNA or mRNA pattern.
In the present study we demonstrate that 15% of the
patients with non-metastatic breast cancer have DTCs
detected in BM after primary surgery (Table 4). Al-
though the use of different methodologies complicates a
direct comparison between the studies, our results seem
to correspond with Wiedswang et al. (2004) also show-
ing that 15% of the non-metastatic breast cancer patients
had detectable DTCs in BM at a median 66 months
from diagnosis [6]. Janni et al. (2005) detected DTCs in
13% of the patients after surgery [7]. An European
pooled analysis involving 676 breast cancer patients also
corroborates our findings; 15.5% of the breast cancer
patients having DTCs detected in BM after surgery, and
this was found to be an independent predictor of subse-
quent reduced breast-cancer specific survival [12]. The
DTC frequency numbers published by Daskalaki et al.
(2009) using real-time RT-PCR for detection of CK19
mRNA-positive DTCs is, however, in contrast to these
results. In their study, 58% of the non-metastatic breast
cancer patients had BM DTCs detected after surgery,
prior to chemotherapy, and 51% after chemotherapy
[10]. The low recurrence rate among the DTC-positive
patients in their study suggests, however, that their assay
is less specific with regard to clinical relevance. Thismay be partly due to a lower threshold for test positivity,
as they have, as opposed to us, not used the highest
determined normal BM level of the marker as a thresh-
old [10].
We observed that the contribution of CK19 to DTC
detection, relative to hMAM and TWIST1, was lower
after surgery than prior to surgery (Table 2). This obser-
vation supports the hypothesis that the DTC population
after surgery may be enriched for tumor cells undergo-
ing EMT (epithelial to mesenchymal transition), being
able to persist in the BM after primary surgery, as
decreased expression of cytokeratins is associated with
the EMT process [21]. A reduction in the number of
CK19-positive patients after surgery has also been
reported previously [9]. These observations also contrast
somewhat with Daskalaki et al. (2009) regarding the
high fraction of patients with CK19-positive DTCs in
BM after surgery in their study [10]. Thus, the change in
the relative contribution of the three markers before and
after surgery observed in our study is an interesting find-
ing, and may suggest a differential marker expression in
the DTCs detected at various sampling time points.
Whether this reflects a general change in the expression
profile of the DTC population present in the BM before
and after surgery, may be a topic of future investigation.
Despite the establishment of the prognostic and pre-
dictive significance of BM DTCs [2,16,19], detection of
DTCs is yet to be adapted in clinical routine staging pro-
cedures. One of the reasons is the challenge of
standardization of methods. This has been addressed for
immunocytochemical methods [22], but not in a similar
way for RT-PCR methods. Additionally, patient discom-
fort and logistical challenges involved with BM sampling
might be a hurdle to routine use. The rapid development
of methods to detect circulating tumor cells (CTCs) in
peripheral blood [23-25], may offer a solution to this
problem if CTCs are demonstrated to be of equivalent
relevance to clinical outcome. However, in non-
metastatic breast cancer patients only a limited number
of studies have so far compared BM and peripheral
ANo at risk DTC  -/- 118 117        111        108        108        106
No at risk DTC  +/- 13 12          10            9            9            9
15 13 12 12 12 12No at risk DTC -/+
No at risk DTC +/+ 8 7 4 4 1 1
B
No at risk DTC  -/- 118        117 114        110        109        108
13 13 13 12 12 12
No 15 15 12 11 11 11 at risk DTC -/+       
No at risk DTC +/-       
No at risk DTC  +/+ 8 7 6 6 3 2
Figure 2 Kaplan Meier estimates according to the presence of disseminated tumor cells in bone marrow before and after surgery.
Kaplan-Meier estimates of systemic recurrence-free survival (A), and breast-cancer specific survival (B) according to the presence of disseminated
tumor cells (DTCs) in bone marrow (BM) only before surgery (DTC +/−, n = 13), only after surgery (DTC −/+, n = 15), both before and after surgery
(DTC +/+, n = 8) and no presence of DTCs in BM (DTC −/−, n = 118). P-values were calculated by the log-rank test. The numbers of patients at risk
are indicated below each plot.
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BM at the same time point from the patients [26-28].
Based on these studies the clinical significance of CTCs
in peripheral blood seems less clear than for DTCs in
BM in this patient group (reviewed in [29]). Neverthe-
less, the clinical utility of the prognostic information
from DTCs will also depend on the development oftreatment options specifically targeting DTCs and CTCs.
Detection and isolation techniques that allow a molecu-
lar characterization of DTCs may provide tools to
guide novel, targeted therapies [29]. However, pres-
ently ASCO guidelines state that the data from DTC
detection in BM and CTC detection in blood, even
in metastatic breast cancer patients, are insufficient
Tjensvoll et al. BMC Cancer 2012, 12:190 Page 10 of 11
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ease for the management of patients with breast
cancer [30]. Further validation in randomized trials
is needed to confirm the clinical value of minimal
residual disease detection.
Conclusion
Detection of DTCs by our MM mRNA panel in BM col-
lected after surgery identified non-metastatic breast can-
cer patients at high risk for systemic relapse, and with
reduced breast-cancer specific survival. Furthermore,
patients with positive DTC status both before and after
surgery are recognized as patients with an extremely
poor prognosis. Thus, a strategy involving a BM aspirate
during general anesthesia, prior to surgery, with a
repeated, post-operative aspiration performed only
among patients who were DTC positive in the first sam-
ple, should be feasible and having significant clinical
relevance. Moreover, although we may not conclude
on the potential of DTC status for monitoring the
efficiency of adjuvant treatment, the strong prognos-
tic effect of DTCs observed after surgery suggests
that such monitoring may be of importance. Future
studies are required to determine whether the
patients with inferior outcome predicted by DTC
detection, especially those with DTCs detected both
before and after surgery, may benefit from intensi-
fied or secondary adjuvant therapy.
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